J. Goldman & Co’s C4 Therapeutics CCCC Stock Holding History

J. Goldman & Co’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-25,930	Closed	-$629K	–	363
2022 Q1	$629K	Buy	+25,930	New	+$630K	0.03%	280

Other funds holding CCCC

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

J. Goldman & Co's CCCC Position: Q2 2022 in Review

J. Goldman & Co sold out of C4 Therapeutics (CCCC) in Q2 2022, closing a stake of 25,930 shares — an estimated $629K sold.

J. Goldman & Co first reported a position in CCCC in Q1 2022 and held it in 1 quarter. The position peaked at $629K in Q1 2022. 113 funds tracked by Wall St. Rank hold CCCC as of Q2 2022.

J. Goldman & Co reported no remaining C4 Therapeutics position as of Q2 2022 after selling out during the quarter.
J. Goldman & Co sold 25,930 C4 Therapeutics shares in Q2 2022, an estimated $629K.
J. Goldman & Co first reported a position in C4 Therapeutics in Q1 2022 and held it in 1 quarter.
J. Goldman & Co's C4 Therapeutics position peaked at $629K in Q1 2022.
113 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2022.

Based on J. Goldman & Co's 13F filing for Q2 2022, filed 15 Aug 2022.